| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | selumetinib:UNC0638 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |